Johnson & Johnson

JNJ · NYSE · Healthcare · Drug Manufacturers General

Next earnings: October 13, 2026 · before the open

$271.22+0.2%Sep 25 close

1M: +1.2%
6M: +14.0%
1Y: +52.7%
5Y: +89.2%

Makes prescription medicines and medical devices for cancer, immune disorders, surgery, heart care, joint replacement and vision.

Built from Johnson & Johnson’s own filings with the SEC. Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Full financial statements →

About Johnson & Johnson

Johnson & Johnson develops, makes and sells prescription medicines and medical devices around the world. Its two businesses are Innovative Medicine, which sells medicines for conditions including cancer and immune disorders, and MedTech, which sells products used in heart procedures, surgery, orthopaedics and vision care.

Head office: New Brunswick, New Jersey
Founded: 1887 (founding year, high confidence)
Employees: 140,800 (December 28, 2025, high confidence)
Listed on: New York Stock Exchange
Financial year ends: Last Sunday in December

How it makes money

Innovative Medicine64%
MedTech36%

Shares of revenue are estimates for six months ended June 28, 2026, high confidence, not figures from a filing.

Competes with

What it sells6

DARZALEX
A medicine used to treat multiple myeloma, a cancer of plasma cells.
TREMFYA
A medicine for conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
CARVYKTI
A treatment made from a patient’s modified immune cells for multiple myeloma that has returned or has not responded to earlier treatment.

Show 3 more

VARIPULSE
A system that uses pulsed electrical energy to treat atrial fibrillation, a disorder that causes an irregular heartbeat.
Impella
A heart pump used to support blood circulation in certain patients with heart failure or during high-risk heart procedures.
ACUVUE
A brand of contact lenses sold for vision correction.

Who buys it4

Wholesalers, distributors and retailers that buy medicines and medical products for resale.
Hospitals and clinics that buy medicines and devices for patient care and procedures.
Physicians and other healthcare professionals who prescribe medicines or use medical devices in treatment.
Eye-care professionals and retailers that supply contact lenses and other vision products.

What it stands on, and what could break it

What the business leans on

1Some medicines rely on licenses or partnerships with other companies. For example, a subsidiary licenses patent families related to DARZALEX from Genmab, and IMBRUVICA is co-commercialized in the United States with Pharmacyclics, an AbbVie company.
2The company depends on government approvals and ongoing oversight for its medicines and medical devices, including rules on safety, manufacturing, labeling and sales.
3

How it compares with its industry

Three ratings, each a percentile against the 21 companies we cover in Drug Manufacturers General. Deliberately kept apart rather than blended into one score — cheap, rising and well-run are three different facts, and a single number would hide which one is which.

Momentum

84of 100 in its industry

Near the top of its industry

12 months to a month ago57.7%

6 months to a month ago12.6%

The most recent month is left out on purpose: returns tend to persist over 7–12 months and the newest one tends to reverse. This describes what the price has done, and says nothing about what it will do.

Value

21of 100 in its industry

Below most of its industry

Profit for the price3.22%

Cash for the price3.40%

Sales for the price14.98%

Assets for the price12.48%

Operating profit for the whole business3.72%

Yields, so higher means cheaper — a loss-making company ranks last instead of dropping out. Cheap is not the same as good: a high yield is often a price that fell for a reason. All five measures available.

Capital allocation

5/5Disciplined

1 check not reported

Return on capital12.7%

Shareholder yield0.91%

Share count, 3 years-9.5%

Net debt / EBITDA1.23x

Insiders, 12 months-$84.4M

What management does with the money — scored on whatever the filings answer, never as a share of the total.

The six capital-allocation checks

Return on the money invested12.7% on invested capital
Debt against earnings1.23x net debt to operating earnings
Cash returned to shareholders0.9% a year in buybacks and dividends
Share count over three yearsShare count 9.5% lower over three years
Payouts covered by cash flowFree cash flow covers what it pays out
Open-market insider buyingNet selling of $84.4M — not counted against the score

A description of where this company sits among its competitors, not a recommendation. Ratings updated Sep 26, 2026.

Sales depend partly on health insurers and government programs deciding whether to cover products and how much they will reimburse; U.S. and other governments can also change medicine-pricing rules.

4The company uses third parties to make or supply some products and relies on complex international manufacturing and distribution chains.

What could go wrong

1Generic and biosimilar competition can reduce sales of medicines when alternatives enter the market. The latest quarterly report describes continuing sales declines for STELARA and says biosimilar competition is also affecting other medicines.
2Government pricing rules, coverage decisions and reimbursement changes can affect what the company receives for medicines and medical devices. The company identifies U.S. drug-pricing measures and tighter regulation across markets as concerns.
3Lawsuits and product-safety claims can lead to substantial costs and affect sales or reputation. The latest quarterly report recorded charges related to talc litigation.